{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T17:00:06Z","timestamp":1790528406554,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T00:00:00Z","timestamp":1585180800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.annonc.2020.03.294","type":"journal-article","created":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T19:51:01Z","timestamp":1585597861000},"page":"780-788","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"title":["Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed\/refractory non-Hodgkin's lymphoma"],"prefix":"10.1016","volume":"31","author":[{"given":"V.","family":"Moreno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Sepulveda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Vieito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Hern\u00e1ndez-Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Doger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Saavedra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Ferrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Sarmiento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Arias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"De Alvaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Di Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Zuraek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Sanchez-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Aronchik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.H.","family":"Filvaroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Nikolova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Bra\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2020.03.294_bib1","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/2040620715576662","article-title":"Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence","volume":"6","author":"Chaidos","year":"2015","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.annonc.2020.03.294_bib2","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrc3256","article-title":"BET domain co-regulators in obesity, inflammation and cancer","volume":"12","author":"Belkina","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.annonc.2020.03.294_bib3","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1056\/NEJMra1112635","article-title":"Targeting epigenetic readers in cancer","volume":"367","author":"Dawson","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2020.03.294_bib4","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1093\/annonc\/mdx157","article-title":"BET inhibitors: a novel epigenetic approach","volume":"28","author":"Doroshow","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2020.03.294_bib5","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.molcel.2014.05.016","article-title":"The mechanisms behind the therapeutic activity of BET bromodomain inhibition","volume":"54","author":"Shi","year":"2014","journal-title":"Mol Cell"},{"key":"10.1016\/j.annonc.2020.03.294_bib6","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2020.03.294_bib7","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2217\/epi.14.91","article-title":"Targeting BET bromodomains for cancer treatment","volume":"7","author":"Jung","year":"2015","journal-title":"Epigenomics"},{"key":"10.1016\/j.annonc.2020.03.294_bib8","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12943-018-0915-9","article-title":"BRD4 and cancer: going beyond transcriptional regulation","volume":"17","author":"Donati","year":"2018","journal-title":"Mol Cancer"},{"key":"10.1016\/j.annonc.2020.03.294_bib9","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1159\/000472407","article-title":"Inhibition of BRD4 suppresses cell proliferation and induces apoptosis in renal cell carcinoma","volume":"41","author":"Wu","year":"2017","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.annonc.2020.03.294_bib10","first-page":"2503","article-title":"Inhibition of BRD4 suppresses tumor growth in prostate cancer via the enhancement of FOXO1 expression","volume":"53","author":"Tan","year":"2018","journal-title":"Int J Oncol"},{"key":"10.1016\/j.annonc.2020.03.294_bib11","first-page":"E5352","article-title":"Uncovering BRD4 hyperphosphorylation associated with cellular transformation in NUT midline carcinoma","volume":"114","author":"Wang","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.annonc.2020.03.294_bib12","doi-asserted-by":"crossref","first-page":"CT014","DOI":"10.1158\/1538-7445.AM2016-CT014","article-title":"Abstract CT014: GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of a phase I\/II open-label single-agent study in patients with NUT midline carcinoma (NMC) and other cancers","volume":"76","author":"O'Dwyer","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2020.03.294_bib13","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1158\/1541-7786.MCR-18-1279","article-title":"BRD4 regulates metastatic potential of castration-resistant prostate cancer through AHNAK","volume":"17","author":"Shafran","year":"2019","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.annonc.2020.03.294_bib14","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1158\/1078-0432.CCR-14-1561","article-title":"The BET bromodomain inhibitor OTX015 affects pathogenetic pathways in preclinical B-cell tumor models and synergizes with targeted drugs","volume":"21","author":"Boi","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2020.03.294_bib15","doi-asserted-by":"crossref","first-page":"11365","DOI":"10.1073\/pnas.1411701111","article-title":"Blockade of oncogenic IkappaB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors","volume":"111","author":"Ceribelli","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.annonc.2020.03.294_bib16","doi-asserted-by":"crossref","first-page":"19408","DOI":"10.1073\/pnas.1216363109","article-title":"Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins","volume":"109","author":"Lockwood","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.annonc.2020.03.294_bib17","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1158\/1940-6207.CAPR-17-0264","article-title":"Chemoprevention of preclinical breast and lung cancer with the bromodomain inhibitor I-BET 762","volume":"11","author":"Zhang","year":"2018","journal-title":"Cancer Prev Res"},{"key":"10.1016\/j.annonc.2020.03.294_bib18","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/bjh.14803","article-title":"Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma","volume":"178","author":"Bernasconi","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.annonc.2020.03.294_bib19","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00247-1","article-title":"Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study","volume":"3","author":"Berthon","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.annonc.2020.03.294_bib20","doi-asserted-by":"crossref","unstructured":"Falchook G, Talpaz M, Mita M. Phase 1\/2 study of INCB054329, a bromodomain and extraterminal (BET) protein inhibitor, in patients with advanced malignancies. AACR-National Cancer Institute-European Organization for Research and Treatment of Cancer International Conference 2017:Abstract A093.","DOI":"10.1158\/1535-7163.TARG-17-A093"},{"key":"10.1016\/j.annonc.2020.03.294_bib21","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(16)00021-1","article-title":"Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study","volume":"3","author":"Amorim","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.annonc.2020.03.294_bib22","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.2018.78.2292","article-title":"Phase Ib trial with birabresib, a small-molecule inhibitor of bromodomain and extraterminal proteins, in patients with selected advanced solid tumors","volume":"36","author":"Lewin","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl_3","key":"10.1016\/j.annonc.2020.03.294_bib23","article-title":"A phase I study of CPI-0610, a bromodomain and extra terminal protein (BET) inhibitor in patients with relapsed or refractory lymphoma","volume":"29","author":"Blum","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2020.03.294_bib24","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2020.03.294_bib25","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2020.03.294_bib26","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1007\/s00259-013-2435-6","article-title":"An international confirmatory study of the prognostic value of early PET\/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and DeltaSUVmax","volume":"40","author":"Itti","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.annonc.2020.03.294_bib27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3109\/10428194.2013.802784","article-title":"Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 3-5 October 2012","volume":"55","author":"Meignan","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.annonc.2020.03.294_bib28","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group","volume":"28","author":"Wen","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"13 Supplement","key":"10.1016\/j.annonc.2020.03.294_bib29","article-title":"Abstract LB-038: Preclinical development and clinical validation of a whole blood pharmacodynamic marker assay for the BET bromodomain inhibitor ZEN-3694 in metastatic castration-resistant prostate cancer (mCRPC) patients","volume":"77","author":"Tsujikawa","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2020.03.294_bib30","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1158\/2159-8290.CD-17-0605","article-title":"BET proteins as targets for anticancer treatment","volume":"8","author":"Stathis","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2020.03.294_bib31","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1182\/blood.V126.23.1491.1491","article-title":"BET Inhibitor CPI-0610 is well tolerated and induces responses in diffuse large B-cell lymphoma and follicular lymphoma: preliminary analysis of an ongoing Phase 1 study","volume":"126","author":"Abramson","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2020.03.294_bib32","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s40262-015-0327-6","article-title":"Phase I population pharmacokinetic assessment of the oral bromodomain inhibitor OTX015 in patients with haematologic malignancies","volume":"55","author":"Odore","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.annonc.2020.03.294_bib33","doi-asserted-by":"crossref","first-page":"25521","DOI":"10.1038\/srep25521","article-title":"Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth","volume":"6","author":"Holst","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.annonc.2020.03.294_bib34","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ygyno.2008.10.032","article-title":"Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer","volume":"112","author":"Jongen","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.annonc.2020.03.294_bib35","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1158\/1078-0432.CCR-12-3039","article-title":"Lack of estrogen receptor-alpha is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma","volume":"19","author":"Wik","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2020.03.294_bib36","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1200\/JCO.2013.49.6968","article-title":"Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial","volume":"31","author":"Gilbert","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2020.03.294_bib37","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/ana.21044","article-title":"MGMT methylation: a marker of response to temozolomide in low-grade gliomas","volume":"60","author":"Everhard","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1016\/j.annonc.2020.03.294_bib38","doi-asserted-by":"crossref","first-page":"4689","DOI":"10.1038\/onc.2015.521","article-title":"BET bromodomain inhibitors synergize with ATR inhibitors to induce DNA damage, apoptosis, senescence-associated secretory pathway and ER stress in Myc-induced lymphoma cells","volume":"35","author":"Muralidharan","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.annonc.2020.03.294_bib39","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1158\/1078-0432.CCR-15-1666","article-title":"The bromodomain inhibitor JQ1 and the histone deacetylase inhibitor panobinostat synergistically reduce N-Myc expression and induce anticancer effects","volume":"22","author":"Shahbazi","year":"2016","journal-title":"Clin Cancer Res"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375342036381X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375342036381X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T05:58:04Z","timestamp":1760335084000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375342036381X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S092375342036381X"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2020.03.294","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed\/refractory non-Hodgkin's lymphoma","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2020.03.294","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}